Sunosi Cannot Be Recommended for Idiopathic Hypersomnia Based on Current Guidelines
Solriamfetol (Sunosi) is not recommended for treating idiopathic hypersomnia (IH) because it lacks sufficient evidence for this indication and is notably absent from the American Academy of Sleep Medicine's 2021 clinical practice guidelines for IH treatment.
Current Guideline Recommendations
The 2021 AASM guidelines provide clear treatment hierarchies for idiopathic hypersomnia 1:
Strong Recommendation for IH:
- Modafinil is the only medication with a STRONG recommendation for treating idiopathic hypersomnia in adults
Conditional Recommendations for IH:
- Clarithromycin
- Methylphenidate
- Pitolisant
- Sodium oxybate
Critical Absence:
Solriamfetol is conspicuously absent from all IH recommendations, despite receiving a STRONG recommendation for narcolepsy treatment in the same guideline 1.
FDA-Approved Indications
The FDA label for Sunosi explicitly limits its use to 2:
- Excessive daytime sleepiness associated with narcolepsy
- Excessive daytime sleepiness associated with obstructive sleep apnea (OSA)
Idiopathic hypersomnia is not an FDA-approved indication.
Why This Distinction Matters
The AASM guideline development process used rigorous GRADE methodology to evaluate available evidence 1. The fact that solriamfetol received high-quality evidence ratings and STRONG recommendations for narcolepsy (based on 3 RCTs demonstrating clinically significant improvements) 1 but was not included in IH recommendations indicates insufficient evidence existed to support its use in IH at the time of guideline development.
This is explicitly stated in the guidelines: "The absence of inclusion of certain interventions in this clinical practice guideline should not be interpreted as a statement against their clinical use" but rather reflects that "insufficient evidence existed to make recommendations" 1.
Clinical Algorithm for IH Treatment
Based on the 2021 AASM guidelines 1:
- First-line therapy: Modafinil (STRONG recommendation)
- Second-line options (if modafinil fails or is not tolerated):
- Methylphenidate (CONDITIONAL)
- Pitolisant (CONDITIONAL)
- Sodium oxybate (CONDITIONAL)
- Clarithromycin (CONDITIONAL)
Solriamfetol should not be included in this algorithm for IH based on current evidence-based guidelines.
Important Caveats
- The guidelines note that "insufficient evidence" does not mean an intervention doesn't work, only that evidence is lacking 1
- Off-label use remains at clinician discretion, but should be informed by the lack of supporting evidence
- Recent research reviews 3, 4, 5, 6, 7 discuss solriamfetol's role in hypersomnolence broadly but do not provide IH-specific efficacy data that would change guideline recommendations
- If considering off-label use, patients should be informed about the lack of evidence-based support and FDA approval for this indication